Zymeworks Inc. (ZYME) SEC filings

ZYMENasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30141% above fair value

$26.47−2.60 (-8.94%)

Close on Nov 12, 2026Market cap $1.88BP/E 50.9Yield –

SEC filings

40 of Zymeworks's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 9, 2026	SEC EDGAR
Current report	8-K	Nov 9, 2026	Nov 9, 2026	SEC EDGAR
Proxy statement	DEF 14A	Dec 15, 2026	Oct 26, 2026	SEC EDGAR
Current report	8-K	Oct 22, 2026	Oct 23, 2026	SEC EDGAR
Current report	8-K	Sep 23, 2026	Sep 23, 2026	SEC EDGAR
Current report	8-K	Aug 25, 2026	Aug 25, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Aug 6, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Jun 28, 2026	Jun 29, 2026	SEC EDGAR
Current report	8-K	May 14, 2026	May 14, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 7, 2026	SEC EDGAR
Current report	8-K	May 7, 2026	May 7, 2026	SEC EDGAR
Current report	8-K	Mar 31, 2026	Apr 1, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 2, 2026	SEC EDGAR
Current report	8-K	Mar 2, 2026	Mar 2, 2026	SEC EDGAR
Current report	8-K	Mar 2, 2026	Mar 2, 2026	SEC EDGAR
Current report	8-K	Jan 6, 2026	Jan 12, 2026	SEC EDGAR
Current report	8-K	Dec 30, 2025	Dec 30, 2025	SEC EDGAR
Current report	8-K	Nov 16, 2025	Nov 18, 2025	SEC EDGAR
Current report	8-K	Nov 17, 2025	Nov 17, 2025	SEC EDGAR
Proxy statement	DEF 14A	Dec 30, 2025	Nov 10, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Nov 6, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Sep 2, 2025	Sep 2, 2025	SEC EDGAR
Current report	8-K	Aug 9, 2025	Aug 11, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Aug 7, 2025	Aug 7, 2025	SEC EDGAR
Current report	8-K	Jun 26, 2025	Jun 27, 2025	SEC EDGAR
Current report	8-K	May 30, 2025	May 30, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 8, 2025	SEC EDGAR
Current report	8-K	May 8, 2025	May 8, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 5, 2025	SEC EDGAR
Current report	8-K	Mar 5, 2025	Mar 5, 2025	SEC EDGAR
Current report	8-K	Feb 17, 2025	Feb 18, 2025	SEC EDGAR
Current report	8-K	Jan 8, 2025	Jan 8, 2025	SEC EDGAR
Current report	8-K	Dec 10, 2024	Dec 11, 2024	SEC EDGAR
Current report	8-K	Nov 21, 2024	Nov 21, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Oct 31, 2024	SEC EDGAR
Current report	8-K	Oct 31, 2024	Oct 31, 2024	SEC EDGAR
Proxy statement	DEF 14A	Dec 10, 2024	Oct 29, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Zymeworks's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ZYME.

Compare: ZYME vs XNCR · ZYME vs ANAB · ZYME vs IDYA · ZYME vs NUVB · ZYME vs PBYI

Revenue growth97.8% · median 23.3%

Operating margin16.6% · median -61.2%

Net margin16.3% · median -58.8%

Company	Revenue	Growth
ZYME	$265.97M	+97.8%
IDYA	$234.13M	–
PBYI	$231.83M	+9.4%
NUVB	$201.73M	+654.2%
XNCR	$200.49M	+33.5%
ANAB	$191.57M	+13.0%

Company

Next earnings (est.): Mar 1, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 264
Held by institutions: 98.1%
Auditor: KPMG LLP
SEC CIK: 1937653

Advertisement
300 × 250

See a number that looks wrong?